New analysis from Frost & Sullivan (drugdiscovery.frost.com), European Nucleic Acid-based Amplification Reagents Markets for Clinical Applications, finds that the market earned revenues of $432.0 million in 2007 and estimates this to reach $1,153.0 million in 2014.
"The increase in automation technology and the use of quantitative PCR (qPCR) and multiplexing provides an early, rapid and accurate method to diagnose disease states and medical disorders," notes Frost & Sullivan Research Analyst Bela Sheth. "End users are slowly realising the benefits of being able to detect clinically relevant genetic variations in patients to help doctors better predict disease risk and progression. This allows them to select the most appropriate therapy sooner, which can decrease healthcare costs significantly in the long- term."
There are several tests for infectious diseases that use NAT technology, including for HIV, HBV, HCV, HPV, CT, GC, HSV, CMV, MTB, Legionella species, Mycloplasma pneumoniae, Group A strep, EBV and VZV. The sensitivity and the accuracy of NAT technology and the rise in automation are driving the growth of this segment.
NAT technology for genetic testing is still in its early growth stage, however the completion of the human genome project and the increase in the number of biomarkers that are being identified is catalysing this market. The development of NAT tests for screening purposes, such as for HPV testing and expanded DTC advertising, augurs well for long-term market growth.
However, reimbursement is a key issue in several European countries. While end users have started to recognise the benefits of using NAT technology, the high costs associated with instrumentation and reagents constitute a major concern.
"NAT diagnostic kits can play a very important part in detecting infectious agents, genetic disorders, predicting the likelihood of having cancer and monitoring a therapy," explains Sheth. "However, the major question gripping the industry is whether these technologies are cost effective. The alternative methods for clinical applications such as home-brewed assays, immunoassays, fluorescence in situ hybridisation (FISH) and culture techniques continue to be less expensive than NAT reagents."
With the wide range of alternative technology available in the market to detect infectious agents and medical disorders, price has always been a sensitive issue with regards to NAT technology.
"Therefore, strategies such as educating end users and undertaking widespread marketing to make customers aware of NAT products and their benefits can be useful," advises Sheth. "Focusing on automation and multi-parameter kits can encourage the use of this technology, and promote sustained market growth."
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the European NAT reagents market for clinical applications, then send an email to Patrick Cairns, Corporate Communications, at pcairns_pr[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country. Upon receipt of the above information, an overview will be sent to you by email.
European Nucleic Acid-based Amplification Reagents Markets for Clinical Applications is part of the Drug Discovery Technologies Growth Partnership Service Programme, which also includes research in the following markets: Contract Research Organisations (CROs) Markets in Europe, Nucleic Acid Isolation Markets in Europe and Advances in Laboratory Automation Markets in Europe. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews with the press are available.
Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership™ empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents.
European Nucleic Acid-based Amplification Reagents Markets for Clinical Applications / M218